{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ULBI/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-14T23:55:49.919Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":11246,"canonical_name":"ULTRALIFE CORP","cik":"0000875657","uei":null,"lei":null,"duns":null,"ticker":"ULBI"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":7,"lobbying":1},"count":8,"timeline":[{"ts":"2026-08-07","kind":"sec.filing","form_type":"10-Q","title":"10-Q — ULTRALIFE CORP — 2026-08-07","url_slug":"/sec/cik-0000875657/10-q/0001437749-26-026432","accession_number":"0001437749-26-026432","importance":45},{"ts":"2026-08-07","kind":"sec.filing","form_type":"8-K","title":"8-K — ULTRALIFE CORP — 2026-08-07","url_slug":"/sec/cik-0000875657/8-k/0001437749-26-026573","accession_number":"0001437749-26-026573","importance":35},{"ts":"2026-07-23","kind":"sec.filing","form_type":"8-K","title":"8-K — ULTRALIFE CORP — 2026-07-23","url_slug":"/sec/cik-0000875657/8-k/0001437749-26-024330","accession_number":"0001437749-26-024330","importance":35},{"ts":"2026-06-02","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — ULTRALIFE CORP — 2026-06-02","url_slug":"/sec/cik-0000875657/def-14a/0001437749-26-019134","accession_number":"0001437749-26-019134","importance":40},{"ts":"2026-06-02","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — ULTRALIFE CORP — 2026-06-02","url_slug":"/sec/cik-0000875657/defa14a/0001437749-26-019135","accession_number":"0001437749-26-019135","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"SD","title":"SD — ULTRALIFE CORP — 2026-06-01","url_slug":"/sec/cik-0000875657/sd/0001437749-26-018965","accession_number":"0001437749-26-018965","importance":30},{"ts":"2026-05-18","kind":"sec.insider.p","reporter":"Manna Michael Edward","title":"President and CEO","shares":2000,"price_per_share":6.4693,"usd_value":12939,"security_title":"Ultralife Common Stock; $.10 par value","importance":50.0129386},{"ts":"2026-05-12","kind":"lobbying.filing","reporter":"FOXHOUND ADVISORS","title":"Qs 2026 — RR","security_title":"ULTRALIFE","usd_value":null,"accession_number":"c25b1a59-0c9e-456e-9b15-360ff32a9c85","excerpt":"DEF","importance":25}]}